Bright Minds Biosciences (DRUG) Profit After Tax (2020 - 2026)

Bright Minds Biosciences (DRUG) has 7 years of Profit After Tax data on file, last reported at -$7.6 million in Q1 2026.

• Quarterly Profit After Tax fell 483.85% year-over-year to -$7.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$19.8 million (down 1366.65% YoY) and the FY2025 annual result came in at -$8.9 million, down 332.64% from the prior year.
• Profit After Tax declined to -$7.6 million in Q1 2026, from -$5.4 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $3.5 million in Q1 2022 to a low of -$20.7 million in Q3 2022.
• A 5-year average of -$2.6 million and a median of -$1.1 million in 2023 frame the typical range for Profit After Tax.
• The widest YoY moves for Profit After Tax: up 366.35% in 2025, down 15375.94% in 2025.
• Tracing DRUG's Profit After Tax over 5 years: stood at $1.7 million in 2022, then tumbled by 171.91% to -$1.2 million in 2023, then jumped by 102.87% to $35513.3 in 2024, then plunged by 15375.94% to -$5.4 million in 2025, then plunged by 40.59% to -$7.6 million in 2026.
• The last three Profit After Tax figures came in at -$7.6 million (Q1 2026), -$5.4 million (Q4 2025), and -$3.0 million (Q3 2025), per Business Quant data.